albuterol has been researched along with Smoking Cessation in 11 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide." | 2.52 | Early chronic obstructive pulmonary disease: definition, assessment, and prevention. ( Drummond, MB; Rennard, SI, 2015) |
| "Smoking cessation has been shown to slow lung function decline and to reduce mortality--including deaths due to lung cancer, other respiratory disease (including COPD), and cardiovascular disease." | 2.43 | Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. ( Anzueto, A, 2006) |
| "The prevalence of chronic obstructive pulmonary disease (COPD) in women is increasing, as is hospitalization for COPD." | 1.34 | Gender and chronic obstructive pulmonary disease: why it matters. ( Buist, S; Curtis, JL; Giardino, ND; Han, MK; Mannino, DM; Martinez, FJ; Postma, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rennard, SI | 1 |
| Drummond, MB | 1 |
| Richie, RC | 1 |
| Tillie-Leblond, I | 1 |
| Housset, B | 1 |
| Marchand, E | 1 |
| Restrick, L | 1 |
| Stern, M | 1 |
| Baxter, N | 1 |
| Goldman, CA | 1 |
| Robinson, EM | 1 |
| Goldman, MD | 1 |
| Anzueto, A | 1 |
| Rabe, KF | 1 |
| Beghé, B | 1 |
| Luppi, F | 1 |
| Fabbri, LM | 1 |
| Han, MK | 1 |
| Postma, D | 1 |
| Mannino, DM | 1 |
| Giardino, ND | 1 |
| Buist, S | 1 |
| Curtis, JL | 1 |
| Martinez, FJ | 1 |
| Friedman, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap[NCT03263130] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-01-01 | Recruiting | |||
| Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)[NCT03137303] | Phase 3 | 402 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Determine differences in healthcare visits which include all-cause and respiratory related, acute care outpatient visits, emergency department visits, and hospitalizations between groups (NCT03137303)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergency room visit72551318 | Emergency room visit72551317 | Hospitalization72551317 | Hospitalization72551318 | Acute outpatient visit72551318 | Acute outpatient visit72551317 | Routine primary care visits72551317 | Routine primary care visits72551318 | New diagnostic tests72551318 | New diagnostic tests72551317 | |||||||||||||||||||||
| No | Missing | Yes | ||||||||||||||||||||||||||||
| Patient Subject Usual Care | 111 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 76 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 119 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 93 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 1 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 48 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 17 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 182 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 152 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 61 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 35 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 169 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 134 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 198 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 138 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 32 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 31 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 2 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 126 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 72 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 104 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 97 | |||||||||||||||||||||||||||||
5 reviews available for albuterol and Smoking Cessation
| Article | Year |
|---|---|
Early chronic obstructive pulmonary disease: definition, assessment, and prevention.
Topics: Albuterol; Androstadienes; Anti-Inflammatory Agents; Bronchodilator Agents; Disease Progression; Dru | 2015 |
[Long-term trials assessing pharmacological treatments in COPD: lessons and limitations].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Broncho | 2010 |
Something old, something new, something borrowed. COPD treatment today.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Anti-Inflammatory Agents; Beclomethasone; Br | 2006 |
Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Bronchodil | 2006 |
Update in chronic obstructive pulmonary disease 2006.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Diagnostic Imaging; Fluticasone; Humans; Immunity, | 2007 |
6 other studies available for albuterol and Smoking Cessation
| Article | Year |
|---|---|
Assessing mortality risk in COPD.
Topics: Actuarial Analysis; Albuterol; Androstadienes; Body Mass Index; Bronchial Hyperreactivity; Bronchodi | 2008 |
[Debates surrounding COPD].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Inflammatory Ag | 2010 |
Tiotropium versus salmeterol in COPD.
Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Humans; Pulmonary Disease, Chronic Obs | 2011 |
Gender and chronic obstructive pulmonary disease: why it matters.
Topics: Administration, Inhalation; Albuterol; Anti-Inflammatory Agents; Bronchodilator Agents; Female; Huma | 2007 |
Changing practices in COPD. A new pharmacologic treatment algorithm.
Topics: Administration, Inhalation; Albuterol; Algorithms; Bronchodilator Agents; Drug Administration Schedu | 1995 |
[What are the options other than smoking cessation? Public health illness COPD calls in experts for the plan].
Topics: Albuterol; Bronchodilator Agents; Clinical Trials as Topic; Humans; Lung Diseases, Obstructive; Salm | 2001 |